Phase Ib and Expansion Study of Gemcitabine, Nab -Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer
The Oncologist · 2023
DOI: 10.1093/oncolo/oyad002 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Oncologist, 2023. Verfasst von Kimberly Perez und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Hauptthemen laut MEDLINE: Hypoalbuminemia, Pancreatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, AVEO Pharmaceuticals.
Abstract (Originalsprache)
Background
In preclinical pancreatic ductal adenocarcinoma (PDAC) models, inhibition of hepatocyte growth factor (HGF) signaling using ficlatuzumab, a recombinant humanized anti-HGF antibody, and gemcitabine reduced tumor burden.
Methods
Patients with previously untreated metastatic PDAC enrolled in a phase Ib dose escalation study with 3 + 3 design of 2 dose cohorts of ficlatuzumab 10 and 20 mg/kg administered intravenously every other week with gemcitabine 1000 mg/m2 and albumin-bound paclitaxel 125 mg/m2 given 3 weeks on and 1 week off. This was followed by an expansion phase at the maximally tolerated dose of the combination.
Results
Twenty-six patients (sex, 12 male:14 female; median age, 68 years [range, 49-83 years]) were enrolled, 22 patients were evaluable. No dose–limiting toxicities were identified (N = 7 pts) and ficlatuzumab at 20 mg/kg was chosen as the maximum tolerated dose. Among the 21 patients treated at the MTD, best response by RECISTv1.1: 6 (29%) partial response, 12 (57%) stable disease, 1 (5%) progressive disease, and 2 (9%) not evaluable. Median progression-free survival and overall survival times were 11.0 months (95% CI, 7.6-11.4 months) and 16.2 months (95% CI, 9.1 months to not reached), respectively. Toxicities attributed to ficlatuzumab included hypoalbuminemia (grade 3, 16%; any grade, 52%) and edema (grade 3, 8%; any grade, 48%). Immunohistochemistry for c-Met pathway activation demonstrated higher tumor cell p-Met levels in patients who experienced response to therapy.
Conclusion
In this phase Ib trial, ficlatuzumab, gemcitabine, and albumin-bound paclitaxel were associated with durable treatment responses and increased rates of hypoalbuminemia and edema.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
- Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
- Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO, USA.
ORCID-Profile: Kimberly Perez
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- AVEO Pharmaceuticals
Zitieren
APA
Perez, K., Chiarella, A. M., Cleary, J. M., Horick, N., Weekes, C., Abrams, T., Blaszkowsky, L., Enzinger, P., Giannakis, M., Goyal, L., Meyerhardt, J. A., Rubinson, D., Yurgelun, M. B., Goessling, W., Giantonio, B. J., Brais, L., Germon, V., Stonely, D., Raghavan, S., …, & Wolpin, B. M. (2023). Phase Ib and Expansion Study of Gemcitabine, Nab -Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyad002
Vancouver
Perez K, Chiarella AM, Cleary JM, Horick N, Weekes C, Abrams T, et al. Phase Ib and Expansion Study of Gemcitabine, Nab -Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. The Oncologist. 2023. doi:10.1093/oncolo/oyad002
BibTeX
@article{Perez2023,
author = {Perez, Kimberly and Chiarella, Anna M and Cleary, James M and Horick, Nora and Weekes, Colin and Abrams, Thomas and Blaszkowsky, Lawrence and Enzinger, Peter and Giannakis, Marios and Goyal, Lipika and Meyerhardt, Jeffrey A and Rubinson, Douglas and Yurgelun, Matthew B and Goessling, Wolfram and Giantonio, Bruce J and Brais, Lauren and Germon, Victoria and Stonely, Danielle and Raghavan, Srivatsan and Bakir, Basil and Das, Koushik and Pitarresi, Jason R and Aguirre, Andrew J and Needle, Michael and Rustgi, Anil K and Wolpin, Brian M},
title = {Phase Ib and Expansion Study of Gemcitabine, Nab -Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyad002}
}
EUVIMED